Hanmi Pharm

Update in progress

128940.KS (KSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Hanmi Pharm. Co., Ltd. is a South Korea-based biopharmaceutical company focused on developing and selling medicines worldwide, including Korea, China, Japan, and the United States. It targets areas with high unmet medical needs such as obesity, metabolism, oncology, and rare diseases. Its product Gugutams combines tamsulosin and tadalafil for obstructive prostatic growth and erectile dysfunction. Hanmi collaborates with MEDIC Life Sciences to identify cancer biomarkers. Founded in 1973.

Company score

Sentiment: 0.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.23; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.12; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive